65 Publications (Page 1 of 3)
2021
Raloxifene reduces sex- and age-related intervertebral disc degeneration in mice by estrogen signaling
Bhadouria, NeharikaBhadouria, NeharikaBhadouria, NeharikaNiziolek, PaulNiziolek, PaulNiziolek, PaulJordi, Omar ElJordi, Omar ElJordi, Omar ElBerman, Alicia GBerman, Alicia GBerman, Alicia GMcKinzie, DavidMcKinzie, DavidMc Kinzie, DavidWallace, Joseph MWallace, Joseph MWallace, Joseph MHolguin, NilssonHolguin, Nilsson and Holguin, Nilsson
Cold Spring Harbor Laboratory
2020
Genetic Background and Sex: Impact on Generalizability of Research Findings in Pharmacology Studies
Sukoff Rizzo, Stacey JMcTighe, Stephanie and Mc Kinzie, David L
Handbook of experimental pharmacology, vol. 257, pp. 147, 2020-00-00. | Journal Article
2018
P1‐114: MEASUREMENT OF ENDOGENOUS MOUSE TAU IN CEREBROSPINAL FLUID FROM AGED PDAPP MICE FOLLOWING TREATMENT WITH AB‐LOWERING COMPOUNDS
Reising, Nicholas CDay, Theresa AHole, Justin TTingley, Francis DavidGonzalez-DeWhitt, Patricia AMergott, Dustin JMc Kinzie, David LDemattos, Ronald BHayashi, Mansuo L and Riddell, David R
Alzheimer's & Dementia, vol. 14, (no. 7S_Part_5), pp. P314, July 2018. | Journal Article
2014
LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn, Linda MWitkin, Jeffrey MStatnick, Michael AEberle, Elizabeth LMcKinzie, Jamie HKahl, Steven DForster, Beth MWong, Conrad JLi, XiaCrile, Robert SShaw, David BSahr, Allison EAdams, Benjamin LQuimby, Steven JDiaz, NuriaJimenez, AlmaPedregal, ConcepcionMitch, Charles HKnopp, Kelly LAnderson, Wesley HCramer, Jeffrey W and Mc Kinzie, David L
Neuropharmacology, vol. 77, pp. 131-44, 2014/Feb. | Journal Article
2013
Discovery of (1R,2R)-N-(4-(6-isopropylpyridin-2-yl)-3-(2-methyl-2H-indazol-5-yl)isothiazol-5-yl)-2-methylcyclopropanecarboxamide, a potent and orally efficacious mGlu5 receptor negative allosteric modulator.
Hao, JunliangDehlinger, VeroniqueFivush, Adam MRudyk, Helene CBritton, Thomas CHollinshead, Sean PVokits, Benjamin PClark, Barry PHenry, Steven SMassey, Steven MPeng, LanguDressman, Bruce AHeinz, Beverly ARoberts, Edda FBracey-Walker, Mallorie RSwanson, StevenCatlow, John TLove, Patrick LTepool, Anita DPeters, Steven CSimmons, Rosa MIyengar, SmritiMc Kinzie, David L and Monn, James A
Bioorganic & medicinal chemistry letters, vol. 23, (no. 5), pp. 1249-52, 2013/Mar/1. | Journal Article
 
Synthesis and pharmacological characterization of 4-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates: identification of new potent and selective metabotropic glutamate 2/3 receptor agonists.
Monn, James AValli, Matthew JMassey, Steven MHao, JunliangReinhard, Matthew RBures, Mark GHeinz, Beverly AWang, XushanCarter, Joan HGetman, Brian GStephenson, Gregory AHerin, MarcCatlow, John TSwanson, StevenJohnson, Bryan GMc Kinzie, David L and Henry, Steven S
Journal of medicinal chemistry, vol. 56, (no. 11), pp. 4442-55, 2013/Jun/13. | Journal Article
 
The muscarinic acetylcholine receptor agonist BuTAC mediates antipsychotic-like effects via the M4 subtype.
Watt, Marla LRorick-Kehn, LindaShaw, David BKnitowski, Karen MQuets, Anne TChesterfield, Amy KMc Kinzie, David L and Felder, Christian C
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol. 38, (no. 13), pp. 2717-26, 2013/Dec. | Journal Article
2012
Effects of naltrexone and LY255582 on ethanol maintenance, seeking, and relapse responding by alcohol-preferring (P) rats.
Dhaher, RonnieToalston, Jamie EHauser, Sheketha RBell, Richard LMc Kinzie, David LMc Bride, William J and Rodd, Zachary A
Alcohol (Fayetteville, N.Y.), vol. 46, (no. 1), pp. 17-27, 2012/Feb. | Journal Article
 
Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia
Fell, Matthew JMc Kinzie, David LMonn, James A and Svensson, Kjell A
Neuropharmacology, vol. 62, (no. 3), pp. 1473-1483, 2012. | Journal Article
 
Muscarinic mechanisms in psychotic disorders.
Mc Kinzie, David L and Bymaster, Frank P
Handbook of experimental pharmacology, (no. 213), pp. 233-65, 2012. | Journal Article
 
The long-lasting effects of JDTic, a kappa opioid receptor antagonist, on the expression of ethanol-seeking behavior and the relapse drinking of female alcohol-preferring (P) rats.
Deehan, Gerald AMc Kinzie, David LCarroll, F IMc Bride, William J and Rodd, Zachary A
Pharmacology, biochemistry, and behavior, vol. 101, (no. 4), pp. 581-7, 2012/Jun. | Journal Article
2011
Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.
Mitch, Charles HQuimby, Steven JDiaz, NuriaPedregal, Concepcionde la Torre, Marta GJimenez, AlmaShi, QingCanada, Emily JKahl, Steven DStatnick, Michael AMc Kinzie, David LBenesh, Dana RRash, Karen S and Barth, Vanessa N
Journal of medicinal chemistry, vol. 54, (no. 23), pp. 8000-12, 2011/Dec/8. | Journal Article
2010
Molecular mechanisms of action and in vivo validation of an M4 muscarinic acetylcholine receptor allosteric modulator with potential antipsychotic properties.
Leach, KatieLoiacono, Richard EFelder, Christian CMc Kinzie, David LMogg, AdrianShaw, David BSexton, Patrick M and Christopoulos, Arthur
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, vol. 35, (no. 4), pp. 855-69, 2010/Mar. | Journal Article
 
The Orexin-1 Receptor Antagonist SB-334867 Reduces Alcohol Relapse Drinking, but not Alcohol-Seeking, in Alcohol-Preferring (P) Rats.
Dhaher, RonnieDhaher, RonnieHauser, Sheketha RHauser, Sheketha RGetachew, BrukGetachew, BrukBell, Richard LBell, Richard LMcBride, William JMc Bride, William JMcKinzie, David LMc Kinzie, David LRodd, Zachary A and Rodd, Zachary A
Journal of addiction medicine, vol. 4, (no. 3), pp. 153-9, 2010/Sep. | Journal Article
2009
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
Fell, Matthew JPerry, Kenneth WFalcone, Julie FJohnson, Bryan GBarth, Vanessa NRash, Karen SLucaites, Virginia LThrelkeld, Penny GMonn, James AMc Kinzie, David LMarek, Gerard JSvensson, Kjell A and Nelson, David L
The Journal of pharmacology and experimental therapeutics, vol. 331, (no. 3), pp. 1126-36, 2009/Dec. | Journal Article
 
Stress-related neuropeptides and alcoholism: CRH, NPY, and beyond.
Ciccocioppo, RobertoCiccocioppo, RobertoGehlert, Donald R.Gehlert, Donald RRyabinin, AndreyRyabinin, AndreyKaur, SimranjitKaur, SimranjitCippitelli, AndreaCippitelli, AndreaThorsell, AnnikaThorsell, AnnikaLê, Anh DLê, Anh D.Hipskind, Philip AHipskind, Philip A.Hamdouchi, ChafiqHamdouchi, ChafiqLu, JianliangLu, JianliangHembre, Erik JHembre, Erik J.Cramer, JeffreyCramer, JeffreySong, MinSong, MinMc Kinzie, David LMcKinzie, DavidMorin, MichelleMorin, MichelleEconomidou, DainaEconomidou, DainaStopponi, SerenaStopponi, SerenaCannella, NazzarenoCannella, NazzarenoBraconi, SimoneBraconi, SimoneKallupi, MarsidaKallupi, Marsidade Guglielmo, Giordanode Guglielmo, GiordanoMassi, MaurizioMassi, MaurizioGeorge, David TGeorge, David T.Gilman, JodyGilman, JodyHersh, Jacqueline RHersh, JacquelineTauscher, Johannes T.Tauscher, Johannes THunt, Stephen PHunt, Stephen P.Hommer, DanielHommer, DanielHeilig, Markus and Heilig, Markus
Alcohol (Fayetteville, N.Y.), vol. 43, (no. 7), pp. 491-8, 2009/Nov. | Journal Article
2008
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.
Chan, W YMc Kinzie, David LBose, SMitchell, S NWitkin, J MThompson, R CChristopoulos, ArthurLazareno, SBirdsall, N JBymaster, F P and Felder, C C
Proceedings of the National Academy of Sciences of the United States of America, vol. 105, (no. 31), pp. 10978-83, 2008/Aug/5. | Journal Article
 
Autonomic activation associated with ethanol self-administration in adult female P rats.
Bell, RichardRodd, Zachary AToalston, Jamie EMc Kinzie, David LLumeng, LawrenceLi, Ting KaiMc Bride, William J and Murphy, James M
Pharmacology, biochemistry, and behavior, vol. 91, (no. 2), pp. 223-32, 2008/Dec. | Journal Article
 
Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia
Shekhar, AnanthaPotter, William ZLightfoot, JeffreyLienemann, JohnDubé, SanjayMallinckrodt, CraigBymaster, Frank PMc Kinzie, David L and Felder, Christian C
The American Journal of Psychiatry, vol. 165, (no. 8), pp. 1033-9, Aug 2008. | Journal Article
2007
Effects of kappa opioid receptor agonists on attention as assessed by a 5-choice serial reaction time task in rats.
Shannon, Harlan EEberle, Elizabeth LMitch, Charles HMc Kinzie, David L and Statnick, Michael A
Neuropharmacology, vol. 53, (no. 8), pp. 930-41, 2007/Dec. | Journal Article
 
In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders
Rorick-Kehn, Linda MJohnson, Bryan GKnitowski, Karen MSalhoff, Craig RWitkin, Jeffrey MPerry, Kenneth WGriffey, Kelly ITizzano, Joseph PMonn, James AMc Kinzie, David L and Schoepp, Darryle D
Psychopharmacology, vol. 193, (no. 1), pp. 121-36, Jul 2007. | Journal Article
 
Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039).
Rorick-Kehn, Linda MJohnson, Bryan GBurkey, Jennifer LWright, Rebecca ACalligaro, David OMarek, Gerard JNisenbaum, Eric SCatlow, John TKingston, Ann EGiera, Deborah DHerin, Marc FMonn, James AMc Kinzie, David L and Schoepp, Darryle D
The Journal of pharmacology and experimental therapeutics, vol. 321, (no. 1), pp. 308-17, 2007/Apr. | Journal Article
2006
Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344.
Rorick-Kehn, Linda MRorick-Kehn, Linda MPerkins, Everett JPerkins, Everett JKnitowski, Karen MKnitowski, Karen MHart, John CHart, John CJohnson, Bryan GJohnson, Bryan GSchoepp, Darryle DSchoepp, Darryle DMc Kinzie, David L and McKinzie, David L
The Journal of pharmacology and experimental therapeutics, vol. 316, (no. 2), pp. 905-13, 2006/Feb. | Journal Article
 
Melanin-Concentrating Hormone-1 Receptor Modulates Neuroendocrine, Behavioral, and Corticolimbic Neurochemical Stress Responses in Mice
Smith, Daniel GDavis, Richard JRorick-Kehn, LindaMorin, MichelleWitkin, Jeffrey MMc Kinzie, David LNomikos, George G and Gehlert, Donald R
Neuropsychopharmacology, vol. 31, (no. 6), pp. 1135-45, Jun 2006. | Journal Article
 
Preclinical evaluation of melanin-concentrating hormone-1 receptor antagonist for the treatment of obesity and psychiatric disorders
Gehlert, D.RDavis, Richard JRorick-Kehn, LindaWitkin, Jeffrey MMc Kinzie, David LSong, MinMorin, MichelleNomikos, George G and Smith, Daniel G
Neuropeptides, vol. 40, (no. 6), pp. 429, 2006. | Journal Article